The Pharma Data

MAY 27, 2022

million cans of several varieties of its infant formula such as stage 1 and 2 cans of Bubs Organic Grass Fed, Bubs Supreme A2 Beta-Casein Protein and Bubs Easy-digest Goat Milk, that will make at least 27.5 Under the agency’s recent increased flexibilities , Bubs Australia plans to provide at least 1.25 million full-size, 8-ounce bottles.

Production 52

Production Manufacturing Cosmetics Allergies 52

Intouch Solutions

JUNE 30, 2022

47% of those had made in-game purchases, and 37% had purchased virtual cosmetic items. But brands are increasingly going to have to address this unfamiliarity, and normalize therapeutics that aren’t just made out of cellulose and proteins. And 79% of their 3,000 survey respondents said that they had already – not someday!

Pharmacy 52

Pharmacy Radiology Cosmetics Manufacturing 52

XTalks

APRIL 14, 2021

Scientists used synthetic biology and computational protein design tools to develop an enzymatic process to transform red cabbage anthocyanins into their desired color. The US Food and Drug Administration (FDA) defines color additives as “any substance that imparts color to a food, drug, cosmetic, or the human body.

Regulation 94

Regulation Production Branding Cosmetics 94

XTalks

FEBRUARY 8, 2021

They include proteins, monoclonal antibodies and vaccines that are considered to be “ highly similar ” to biological products that have already been approved by the FDA. To date, the FDA has approved 29 biosimilars, 19 of which are currently being marketed. What is a Biosimilar?

Production 78

Production Insulin Branding Generic Drugs 78

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). For additional information, please visit [link]. About Crescita Therapeutics Inc.

Licensing 40

Licensing Licensing Dermatology Production 40

Pfizer

DECEMBER 13, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

Drugs 110

Drugs Licensing Licensing Production 110

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33 Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pfizer

DECEMBER 20, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. IMPORTANT SAFETY INFORMATION.

Drugs 69

Drugs Licensing Licensing Containment 69

The Pharma Data

FEBRUARY 4, 2021

– Full-Year Global Net Revenues from the Aesthetics Portfolio Were $2.590 Billion; Global Botox Cosmetic Net Revenues Were $1.112 Billion. Global Botox Cosmetic net revenues were $493 million , an increase of 9.1 – Reports Fourth-Quarter Diluted EPS of $0.01 percent on a reported basis, or 45.0 Recorded a $4.7

Botox 52

Botox Production Sales Cosmetics 52

Pfizer

NOVEMBER 23, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. PAXLOVID is currently authorized for conditional or emergency use in more than 70 countries across the globe.

Licensing 40

Licensing Licensing Drugs Manufacturing 40